908 Devices Inc.
908 Devices develops handheld chemical analysis devices for government and life sciences customers, including law enforcement, military, first responders, and customs and border personnel. Its products use mass spectrometry and optical spectroscopy, along with analytics and machine learning, to identify chemical substances at the point of need. The portfolio includes the MX908 mass spectrometer and the XplorIR, ThreatID, ProtectIR and VipIR spectroscopy devices. InterceptIR is a headless variant of XplorIR designed for integration with robotic platforms. 908 Devices sells devices worldwide through direct sales and domestic and international channel partners. It also sells consumables, accessories, extended warranty plans, technical support and training. The company assembles and tests products primarily in-house, with manufacturing facilities in Danbury, Connecticut, and precision machining facilities in Stamford, Connecticut, and Georgetown, Massachusetts. Its research and development operations are in Burlington, Massachusetts, and Danbury, Connecticut.
Stifel raised its price target on 908 Devices (NASDAQ:MASS) to $14.00 from $12.00, citing strong execution and record quarterly performance. The company reported 35% revenue growth and raised full-year sales guidance, though it remains unprofitable. The stock has gained 69% over the past year but may be overvalued, according to InvestingPro analysis.
908 Devices (NASDAQ:MASS) reported 35% YoY revenue growth to $19.0M in Q3 2026, raising full-year guidance to $68.5M-$70.0M. Shares fell 4.43% premarket. The company focuses on chemical detection tools for public safety and defense, with FTIR products contributing 55% of revenue. Despite narrowing losses, concerns remain over customer concentration and adjusted EBITDA losses.
908 Devices Inc. (MASS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue Revenue increased 35% compared to prior year Raises low end of 2026 revenue outlook BURLINGTON, Mass. – November 10, 2026 – 908 Devices Inc. (Nasdaq: MASS), a core small-cap
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning MASS (908 Devices Inc.). Coverage has skewed bullish: 4 bullish, 1 neutral, and 2 bearish.
Recent MASS coverage spans earnings, insider activity and financial news.
In the last 30 days, MASS insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($329K). The most active reporter was Brown Christopher D. with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Target raise suggests upside potential.
Shares fell 4.4% pre‑market despite guidance raise, indicating pressure from earnings‑related concerns.
Raised guidance may lift the stock as investors price in stronger top-line growth.
Strong revenue growth and raised guidance support continued upside.
The insider sale modestly increases supply pressure on MASS.
AlphAI scores every news story that mentions MASS with an AI model for sentiment and relevance, and aggregates insider trades from 908 Devices Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Stifel raised its price target on 908 Devices (NASDAQ:MASS) to $14.00 from $12.00, citing strong execution and record quarterly performance. The company reported 35% revenue growth and raised full-year sales guidance, though it remains unprofitable. The stock has gained 69% over the past year but may be overvalued, according to InvestingPro analysis.
908 Devices (NASDAQ:MASS) reported 35% YoY revenue growth to $19.0M in Q3 2026, raising full-year guidance to $68.5M-$70.0M. Shares fell 4.43% premarket. The company focuses on chemical detection tools for public safety and defense, with FTIR products contributing 55% of revenue. Despite narrowing losses, concerns remain over customer concentration and adjusted EBITDA losses.
908 Devices Inc. (MASS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue Revenue increased 35% compared to prior year Raises low end of 2026 revenue outlook BURLINGTON, Mass. – November 10, 2026 – 908 Devices Inc. (Nasdaq: MASS), a core small-cap
Kodiak Sciences (KOD) rose 3% to $104 after positive Phase 3 trial results. 908 Devices (MASS) hit $12.93 with Q2 revenue up 23%. Orchestra BioMed (OBIO) reached $6.20, expanding Q2 loss by 23%. CareDx (CDNA) hit a 52-week high with Q2 revenue up 52%. PMV Pharmaceuticals (PMVP) rose 4% to $1.91 on positive clinical data.
AWM Investment Company, Inc. sold 18,000 indirectly-held shares of 908 Devices Inc. (MASS) at $11.52 ($0.21M total) on 2026-09-29.
AWM Investment Company, Inc. sold 25,000 indirectly-held shares of 908 Devices Inc. (MASS) at an average of $11.36 ($11.25–$11.36, $0.28M total) across 2 trades over 2026-09-23 to 2026-09-24.
AWM Investment Company, Inc. sold 50,000 indirectly-held shares of 908 Devices Inc. (MASS) at an average of $10.60 ($10.52–$10.61, $0.53M total) across 2 trades over 2026-08-20 to 2026-08-21.
908 Devices (MASS) discussed its Q2 2026 performance and strategy. It said adjusted EBITDA loss was under $2 million, a 50% year-over-year improvement. The company acquired NIRLAB on May 6 and highlighted a $6 million ProtectIR order in July. It reported shipping 35 VipIR units in Q2 and 750+ FTIR devices over 24 months.
908 Devices (NASDAQ: MASS) reported Q2 operating expenses of $21.2M, down from $21.5M, and narrowed net loss from continuing operations to $11.9M. Adjusted EBITDA loss improved to $1.9M. Cash and marketable securities were $101.5M with no debt. The company raised 2026 revenue guidance to $68M-$70M and expects recurring revenue of $4.9M (31%).
Knopp Kevin J. (President and CEO) sold 149,013 shares of 908 Devices Inc. (MASS) at an average of $9.90 ($9.06–$10.16, $1.48M total) across 4 trades over 2026-08-10 to 2026-08-12 under a Rule 10b5-1 trading plan.
